Nephrotic Syndrome: Patient characteristics, treatment patterns, and related outcomes after treatment with Acthar[®] Gel or comparable standard of care in a large administrative claims database

BACKGROUND

- Nephrotic syndrome (NS) is a kidney disease characterized by the loss of large amounts of protein in the urine. The incidence of nephrotic syndrome in adults is approximately 1-3 per 100,000 adults [1]
- About 20-40% of patients with difficult to treat nephrotic syndrome fail to adequately respond to first-line corticosteroids, classified as steroid-dependent (SDNS) or steroid-sensitive (SSNS). Patients that are steroiddependent have a high corticosteroid (CS) burden and experience frequent relapses, and combined with patients who are steroid resistant, alternative steroid-sparing treatment options are needed [2]
- Patients who don't respond to CS may require more aggressive treatment with other medications, such as calcineurin inhibitors (CNIs) or other alternative treatments (azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, or rituximab) [3]
- Patients who are steroid dependent (SD) or steroid sensitive (SS) with high relapse rates have significantly higher risk of developing end stage renal disease (ESRD) and renal replacement therapy [4]
- Acthar Gel is indicated for Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus [5]

OBJECTIVE

This real-world evidence (RWE) study objective is to characterize NS patients who initiated Acthar Gel or similar comparators used after early line treatment with CS and/or CNIs, and to compare changes in CS use and other NS-related treatments and outcomes, using a large administrative claims database (Symphony Health)

METHODS

This study is a retrospective, observational cohort comparison of NS patients who initiate treatment with Acthar Gel or similar later line standard of care (SOC) comparators (azathioprine, chlorambucil, cyclophosphamide, mycophenolate mofetil, or rituximab) in a large commercial claims database (Symphony Health)

Inclusion criteria:

- > Patients had a confirmed NS ICD-10-CM diagnosis (**NS cohort index date**; N02.8, N04) with either ≥1 inpatient or \geq 2 outpatient claims during the study period (01/01/2016 to 12/31/2022)
- \rightarrow Patients were \geq 18 years old and had 12 months of continuous enrollment pre- and post-index
- > Patients must have at least one record with any activity (diagnosis, medication, procedure or surgery) in the database >180 days before AND >180 days after the index treatment claim
- Patients were excluded if they had a contraindication to Acthar Gel in the 12-month baseline including adrenocortical hyperfunction, systemic fungal infections, congestive heart failure, ocular herpes simplex, osteoporosis, peptic ulcers, primary adrenocortical insufficiency, and scleroderma

Cohort criteria and index dates:

- > Acthar Gel cohort: Patients with any Acthar Gel claim during the study intake period (01/01/2017 to 12/31/2021), with the first Acthar Gel claim as Acthar index date
- SOC comparator cohort: Patients with any claim for a comparable later line therapy used after CS and/or CNIs, similar to Acthar Gel during the study intake period, with first claim as **SOC index date**
- **FSGS, iMN, and IgAN sub-cohorts:** For both Acthar Gel and SOC comparator cohorts, a confirmed diagnosis of the subtype was required before treatment index
- Statistical testing using Chi-square test or Fisher exact test for categorical variables (Acthar Gel cohort vs. SOC cohort in each period), Welch's t-test for continuous variables (Acthar Gel cohort vs. SOC cohort in each period) and McNemar test for categorical variables (Follow-up period vs. Baseline period in each cohort), paired sample t-test for continuous variables (Follow-up period vs. Baseline period in each cohort).


Kyle Hayes¹, Feng-Sheng Hu², Mary Panaccio¹, John Niewoehner, George Wan¹ 1. Mallinckrodt Pharmaceuticals, Bridgwater NJ, USA; 2. KMK Consulting LLC

Table 1. Patient baseline demographics, insurance, and clinical

characteristics						1												Acthar Gel SOC			p-	Acth	ar Gel	SO		p-	Acthar		
		Full Cohort				FSGS cohort				iMN cohort			IgAN cohort			t			СО	mparator n = 6,812)	value***			(n = 6,812)		value***	Gel	com	
				SOC nparator	p-value**		nar Gel	comparator		Acthar Gel		SOC comparator		Acthar Gel		SOC comparator		Outcomes: Treatment pattern and NS related procedures		(n = 315) (n = 6,812) Baseline period*			(n = 315) (n = 6,812) Follow-up period**				Baseline vs. Fol		
	(n = 315)		(n =	= 6,812)		(n = 7	= 72)	(n =	1,077)	(n = 72)		(n = 852)		(n = 36)		(n =	792)	Corticosteroid (CS)											
aseline* characteristics																		# of patients with ≥ 1 fills of corticosteroids (n, %)	209	66% 4,70	02 69%	0.347	162	51%	5,516	81%	<0.001	<0.001	<
ge, (mean, sd)	49.4	18.2	46.1		0.002	46.0		45.7	17.0	54.4	16.7	52.6	16.6	44.1	16.6		15.4	Corticosteroids dosing group, (n, %)											
ale, (n, %)	173	55%	3,306	6 49%	0.031	40	56%	607	56%	43	60%	480	56%	20	56%	433	55%	Intermittent, < 60 days of continuous	75	24% 2,08	38 31%	0.012	62	20%	1,657	24%	0.069	0.228	<
hnicity, (n, %)					0.265													corticosteroid use											
Black/African American	55	17%	934			13	18%	174	16%	12	17%	132	15%	3	8%	35	4%	Extended, ≥60 days of continuous corticosteroid	117	37% 2,29	34%	0.224	80	25%	3,319	49%	<0.001	<0.001	<
White/Caucasian	123	39%	2,660			18	25%	394	37%	39	54%	382	45%	16	44%	344	43%	use											
Hispanic	29	9%	666			8	11%	106	10%	6	8%	85	10%	4	11%	74	9%	Corticosteroid dosing strength, (n, %)	4.0	CO(54		0.000		00/	4 007	4 50(0.010	
Other/Unknown	108	34%	2,552	2 37%		33	46%	403	37%	15	21%	253	30%	13	36%	339	43%	low ($\leq 7.5 \text{ mg/day}$)	19 16	6% 51 5% 37		0.380 0.899	25	8%	1,037	15%	<0.001 0.004	0.210 0.678	
e gion, (n, %)					<0.001													medium (>7.5 to 15 mg/day) high (>15 mg/day)	16 82	5% 37 26% 1,40		0.899	19 36	6% 11%	755 1,527	11% 22%	<0.004	<0.078	
Northeast	64	20%	1,359	9 20%		11	15%	193	18%	16	22%	168	20%	10	28%	173	22%	Averaged daily dose (ADD), (mean, sd)	82 32.1			0.229	21.7	11% 21.1	21.2	22%	0.846	0.001	
Midwest	76	24%	1,839	9 27%		15	21%	260	24%	14	19%	231	27%	7	19%	227	29%	NS background therapies, (n, %)	52.1	21.5 29.	0 24.1	0.225	21.7	21.1	21.2	20.5	0.840	0.001	
South	151	48%	2,463	3 36%		42	58%	463	43%	36	50%	341	40%	16	44%	253	32%	# of patients with ≥ 1 fill, (n, %)	279	89% 5,42	27 80%	0.000	281	89%	5,683	83%	0.006	0.860	0
West	24	8%	1,113	3 16%		4	6%	151	14%	6	8%	110	13%	3	8%	133	17%	ACEi/ARBs		68% 3,7!		0.000	219	70%	3,842	56%	0.000	0.561	(
Other	0	0%	38	1%		0	0%	10	1%	0	0%	2	0%	0	0%	6	1%	Anticoagulants		12% 69		0.392	50	16%	915	13%	0.207	0.019	(
surance type, (n, %)					<0.001													Beta blockers		25% 1,68		0.894	89	28%	1,850	27%	0.698	0.184	C
Commercial	47	15%	2,372	2 35%		11	15%	356	33%	13	18%	303	36%	8	22%	268	34%	Calcium channel blockers	52	17% 82	7 12%	0.028	54	17%	1,018	15%	0.294	0.868	(
Medicaid	38	12%	1,143	3 17%		6	8%	153	14%	5	7%	117	14%	3	8%	98	12%	Diuretics	209	66% 3,4	/1 51%	0.000	212	67%	3,363	49%	0.000	0.813	(
Medicare	68	22%	1,087	7 16%		16	22%	207	19%	21	29%	186	22%	5	14%	110	14%	Statins	173	55% 2,59	3 38%	0.000	173	55%	2,867	42%	0.000	1.000	(
Multiple	37	12%	512	8%		11	15%	104	10%	8	11%	52	6%	3	8%	86	11%	# of unique NS background therapies, (mean, sd)	2.4	1.3 1.9) 1.4	0.000	2.5	1.4	2.0	1.4	0.000	0.072	(
Other/Unknown	125	39%	1,698			27	40%	222	24%	24	35%	177	22%	14	48%	212	29%	# of claims for NS background therapies, (mean,	12.4	10.7 8.4	9.1	0.000	14.2	11.7	10.5	10.3	0.000	0.000	(
DMF-Charlson comorbidity index, (mean, sd)	2.3	1.8	2.5		0.005	2.7	1.8	2.9	1.8	2.2	1.8	2.3	1.8	2.3	1.9	2.7	1.9	sd)											
dividual CDMF Charlson comorbidity, (n, %)																		Calcineurin inhibitors (CNI)											
Myocardial infarction	3	1%	188	3%	0.049	0	0%	31	3%	0	0%	26	3%	0	0%	15	2%	# of patients with ≥ 1 fill, (n, %)		33% 1,4		<0.001	81	26%	2,188	32%	< 0.001	0.008	<
Congestive heart failure	26	8%		8%	0.666	5	7%	64	6%	10	14%	65	8%	4	11%	37	5%	# of claims for CNIs, (mean, sd) Conventional synthetic DMARDs (csDMARD)	2.0	4.3 1.3	3.4	0.005	1.6	4.0	2.8	5.4	<0.001	0.079	<
Peripheral vascular disease	13	4%	475		0.052	7	10%	96	9%	2	3%	63	7%		3%	62	8%	# of patients with ≥ 1 fills of csDMARDs (n, %)	14	4% 92	3 14%	<0.001	13	10/	1,204	18%	<0.001	1.000	
Cerebrovascular disease	18	4 <i>%</i>	247		0.052	5	7%	35	3%	6	8%	48	6%	1	3%	17	2%	# of patients with 21 his of csDMARDs (1, %) # of claims for csDMARDs, (mean, sd)	14 0.2	4% 92 1.1 0.0		<0.001	0.2	4% 1.3	1,204	2.7	<0.001	0.131	
Chronic pulmonary disease	46	15%	873		0.345	5	7%	131	12%	11	15%	124	15%		11%	97	12%	Nonsteroidal anti-inflammatory drugs (NSAIDs)	0.2	1.1 0.0	, 2.0	0.001	0.2	1.5	1.0	2.7	10.001	0.131	
Rheumatic disease	23	7%	1.691		<0.001		3%	27	8%	7	10%	173	20%	2	8%	108	12%	# of patients with ≥ 1 fill, (n, %)	130	41% 2,64	1 39%	0.406	120	38%	2,455	36%	0.495	0.312	<
Liver disease (mild)	20	F 9/	,		0.715			40		, E	7%	1/5		2	8% 6%		14% 7%	# of claims for NSAIDS, (mean, sd)		3.2 1.3		0.171	1.5	3.2	1.3	2.9	0.145	0.867	(
		0%	404				10%	49 84	5%	5		49	6%			56		Opioids	-						-	-			
Diabetes without chronic complication	33	10%	479		0.025	9	13%		8%	0	8%	77	9%	8	22%	51	6%	# of patients with ≥1 fill, (n, %)	157	50% 3,22	20 47%	0.403	142	45%	2,979	44%	0.679	0.199	<
Renal disease (mild, moderate)	192	61%	3,052		<0.001	41	57%	397	37%	48	67%	521	61%	21	58%	296	37%	# of claims for opioids, (mean, sd)	1.9	3.8 1.1	4.5	0.410	2.0	3.9	1.8	4.2	0.342	0.564	(
Diabetes with chronic complication	50	16%			0.276	10	14%	154	14%	14	19%	118	14%	6	17%	111	14%	NS related procedures											
Any malignancy (excluding skin)	12	4%	435		0.073	4	6%	32	3%	5	7%	57	7%	0	0%	25	3%	# of patients with \geq 1 NS related procedure, (n, %)	244	77% 5,6	82%	0.028	235	75%	5,013	74%	0.739	0.368	<
Liver disease (moderate or severe)	0	0%	77	1%	0.050	0	0%	8	1%	0	0%	7	1%	0	0%	8	1%	Dialysis	20	6% 1,10		<0.001	45	14%	823	12%	0.251	<0.001	<
Renal disease (severe)	67	21%	2,012		0.001	27	38%	573	53%	9	13%	139	16%	9	25%	359	45%	Renal transplant		10% 1,3		<0.001	32	10%	1,475	22%	<0.001	0.774	<
GS = Focal segmental glomerulosclerosis, iMN = idiopathic mer aseline period: [index date - 365, index date)	nbranous ne	ephropathy	r, IgAN = Ig	gA nephropat	hy													Renal biopsy		25% 1,8:		0.514	15	5%	500	7%	0.094	<0.001	<
-value calculated using Chi-square test or Fisher exact test for categorical variables (Acthar Gel cohort vs. SOC cohort in each period), Welch's t-test for continuous variables (Acthar Gel cohort vs. SOC cohort in each period) and McNemar test for categorical											ical	Complications of kidney transplant	18	6% 54		0.164	19	6%	681	10%	0.020	1.000	<						
iables (Follow-up period vs. Baseline period in each cohort), p	-												cacir pe		e. temai tesi	or categor		Proteinuria (including Proteinuria test)	225	71% 4,70	04 69%	0.383	206	65%	4,338	64%	0.549	0.061	<

variables (Follow-up period vs. Baseline period in each cohort), paired sample t-test for continuous variables (Follow-up period vs. Baseline period in each co

Figure 1. Treatments used at baseline compared to follow-up



AMCP Nexus 2023, Orlando, FL, October 16-19, 2023

Table 2. Treatment patterns and outcomes in follow-up

aseline period: [index date - 365, index date] lowup period: [index date, index date + 365]

p-value calculated using Chi-square test or Fisher exact test for categorical variables (Acthar Gel cohort vs. SOC cohort in each period), Welch's t-test for continuous variables (Acthar Gel cohort vs. SOC nort in each period) and McNemar test for categorical variables (Follow-up period vs. Baseline period in each cohort), paired sample t-test for continuous variables (Follow-up period vs. Baseline period in

RESULTS

Patients treated with Acthar Gel were older (49 vs. 46 years, p=0.002), with less commercial coverage (15% vs. 35%), similar racial makeup, and lower comorbidity index score $(2.3 \pm 1.8 \text{ vs. } 2.5 \pm 2.0, \text{ p}=0.005)$ compared to the SOC comparator

The Acthar Gel cohort had a significant reduction during follow-up in patients taking CS (66% vs. 51%, p<0.001), patients on extended use CS (≥60 days) (37% to 25%, p<0.001), and average daily dose (ADD) (32.1 ± 21.3 to 21.7 ± 21.1, p=0.001), compared to baseline (Fig. 1A)

Patients in the SOC comparator had a significant increase in the follow-up for patients on CS overall (69% to 81%, p<0.001) and extended use CS (34% to 49%, p<0.001), compared to baseline (Fig. 1A)


The Acthar Gel sub-cohorts for FSGS (n=72), iMN (n=72), and IgAN (n=36) had a similar trends to the overall cohort, with 15%, 13%, and 18% (p=0.033) reduction in proportion of patients on CS therapy, respectively (Fig. 2)

The SOC comparator had significant increases of CS use overall and across all three sub-cohorts (Fig. 2)

The Acthar Gel cohort had an increase in patients on dialysis in the follow-up (6% to 14%, p<0.001), but no change in renal transplants (10% to 10%, p=0.774) or transplant complications (6% to 6%, p=1.000), while the SOC comparator had fewer patients on dialysis (16% to 12%, p<0.001), but an increase in renal transplants (19% to 22%, p<0.001) and transplant complications (8% to 10%, p<0.001)

In addition to CS use, the Acthar Gel cohort had significant reductions in CNI use (7%), overall reduction of NSAIDs and opioids, while the SOC comparator had significant increase of use for CNIs and csDMARDS, and significant decreases for NSAIDs and opioids (Fig. 1B)

Figure 2. Change in corticosteroid use with Acthar Gel compared to SOC by NS subtype



*p<0.05, **p<0.01, ***p<0.001; FSGS=focal segmental glomerulosclerosis, iMN=idiopathic membranous nephropathy, IgAN=IgA nephropath</p>

SOC

< 0.001

<0.001

< 0.001 < 0.001

<0.001 <0.001

<0.001 0.716

<0.001 <0.001

<0.001

<0.001 <0.001

<0.001

- (Fig. 2)
- comparator.

LIMITATIONS AND REFERENCES

References

- Medical Science; 2019
- International 99(3): S1-S87.
- Study. JASN 32(9):p 2303-2314

Mallinckrodt Pharmaceuticals

CONCLUSION

Real-world evidence of nephrotic syndrome patients initiating later line therapy with Acthar Gel had significant reductions in proportion of patients on CS overall, proportion of patients on extended use (>60 days), and average daily dose, while the SOC comparator cohort had significant increases in patients on CS and patients on extended use CS (Table 2)

There was reduction in CS use across the FSGS, iMN, and IgAN sub-cohorts, like the NS cohort overall

Acthar Gel patients had a significant increase in proportion of patients on dialysis, with no change in renal transplant or complications, while the SOC comparator had a significant reduction of patients on dialysis, but significant increases in patients with transplants or transplant complications (Table 2)

Acthar Gel is a viable treatment option for patients that don't respond to CS and/or CNIs. Treatment with Acthar Gel shows a steroid-sparing effect and less need for renal transplant compared to the SOC

This study is limited by the small sample size for patients that initiate Acthar Gel therapy among all NS patients. Due to the small sample size, no exclusion criteria, outside of limiting the data to only adult patients (≥ 18 years old) and patients with contraindicated conditions, was applied before analysis. Other indications for Acthar Gel usage among those diagnosed with NS may also be included in this analysis. Lack of detailed lab values and detailed kidney pathology reports in the claims data prevents true clinical assessment of disease improvement by proteinuria levels and renal glomerular function. This study is limited to commercially insured or Medicare Supplemental health plan members, and as such, results may not be generalizable to government-sponsored health insurance members or those uninsured or underinsured who may not have access to the healthcare resources of interest. This analysis uses claims data which may be limited in the amount of patient information available.

Hull RP, Goldsmith DJA. Nephrotic syndrome in adults. BMJ [Internet]. BMJ; 2008;336:1185–9.

Zhong H, Li H-Y, Zhou T, Weng W. Rituximab therapy in adults with steroid-dependent nephrotic syndrome. Archives of Medical Science. Archives of

Cheung, A. K., et al. (2021). "KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease." Kidney

Go, A. S, et al. (2021) Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome (2019). "Acthar Gel (repository corticotropin injection; prescribing information)." Mallinckrodt ARD LLC., Bedminster, NJ 07921 USA.